Maravai Lifesciences Holdings (MRVI) Total Current Liabilities (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Total Current Liabilities of $42.6 million for Q1 2026, down 32.52% year-over-year from $63.2 million in Q1 2025, and down 5.11% quarter-over-quarter from $44.9 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Total Current Liabilities (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $42.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 32.52% year-over-year to $42.6 million; the TTM figure through Mar 2026 stood at $42.6 million (down 32.52% YoY), while the FY2025 annual figure was $44.9 million, down 21.16% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $42.6 million, down from $44.9 million in the prior quarter.
- The five-year high for Total Current Liabilities was $124.9 million in Q1 2023, with the low at $42.6 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $69.7 million (2025), against an average of $77.7 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 44.1% in 2023, then sank 52.74% in 2024.
- Maravai Lifesciences Holdings' Total Current Liabilities stood at $110.1 million in 2022, then fell by 20.59% to $87.5 million in 2023, then slumped by 34.87% to $57.0 million in 2024, then retreated by 21.16% to $44.9 million in 2025, then declined by 5.11% to $42.6 million in 2026.
- Business Quant data shows MRVI's Total Current Liabilities at $42.6 million in Q1 2026, $44.9 million in Q4 2025, and $61.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 38.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.42 Mn |
| Mar 31, 2026 | 42.62 Mn |
| Dec 31, 2025 | 44.92 Mn |
| Sep 30, 2025 | 61.57 Mn |
| Jun 30, 2025 | 69.68 Mn |
| Mar 31, 2025 | 63.16 Mn |
| Dec 31, 2024 | 56.97 Mn |
| Sep 30, 2024 | 63.71 Mn |
| Jun 30, 2024 | 68.62 Mn |
| Mar 31, 2024 | 59.02 Mn |
| Dec 31, 2023 | 87.47 Mn |
| Sep 30, 2023 | 78.25 Mn |
| Jun 30, 2023 | 74.92 Mn |
| Mar 31, 2023 | 124.90 Mn |
| Dec 31, 2022 | 110.14 Mn |
| Sep 30, 2022 | 115.66 Mn |
| Jun 30, 2022 | 112.53 Mn |
| Mar 31, 2022 | 86.68 Mn |
| Dec 31, 2021 | 93.78 Mn |
| Sep 30, 2021 | 114.35 Mn |